Change in JAK2V617F allele burden from baseline at week 24. n = number of patients with Week 24 JAK2V617 allele burden assessment. N = number of patients treated. #From BL to week 24 or at EOT assessment if the EOT visit is within the week 24 assessment window (169 ± 28 days). The JAK2V617 detection threshold is the assay limit of detection (0.5%). JAK2V617 mutational status (−) may have the allele burden at an undetectable or negligible level. High-risk mutation genes include ASXL1, SRSF2, EZH2, IDH1, IDH2, and U2AF1; the mutational status is considered positive if any one of these genes demonstrates a mutation at a given time point. BL, baseline; EOT, end of treatment; NA, not available; W24, week 24.